Addisons advises Bioxyne Limited (ASX:BXN) on its merger with Breathe Life Sciences Pty Ltd

Law firm Addisons advised health and wellness products company Bioxyne on its acquisition of direct sales health and wellness company Breathe Life Sciences Pty Ltd (BLS).

Bioxyne is an ASX listed company with a focus on clinically effective health and wellness products particularly in the gut and immune health areas. BLS and its subsidiaries (Breathe Life Sciences) manufactures, commercialises and distributes plant-based wellness products and supplements, including CBD, cannabis extracts, vitamins, manuka honey, skin care products and mushroom complexes. Breathe Life Sciences operates in Australia, the UK, Japan and Europe.

The acquisition will enable the combined group to further develop its product range and capitalise on the complementary geographies of the two groups, and enable Bioxyne to broaden its scale of operations.

The Addisons team advising Bioxyne were Partner Li-Jean Chew, Senior Associate Chuanchan (CC) Ma and Solicitor Jamie Feggans.

Partner, Li-Jean Chew, said, “Congratulations to Bioxyne. This is a significant step for our client in its growth strategy and we are pleased to have assisted Bioxyne on this transaction, including the shareholder approval and regulatory conditions for completion”.